The malaria drug is quickly falling out of favor with the medical community as a potential treatment for the disease. On the back of mounting concerns about hydroxychloroquine's safety, global pharmaceutical major Sanofi (NASDAQ:SNY) has quit providing it to COVID-19 patients enrolled in its clinical trials for the drug. It has also put a temporary…
A box of Plaquenil, an anti-malaria drug hydroxychloroquine made by Sanofi, used for years to treat malaria and autoimmune disorders.Alain Pitton | NurPhoto | Getty ImagesFrench drugmaker Sanofi said Friday it is suspending recruitment of new patients for its clinical trials looking at anti-malaria drug hydroxychloroquine as a potential treatment for the coronavirus.The company is also…
The international committee on food safety is reviewing infant formula safety. Published: December 29, 2025, 12:05 am Scientists are to conduct a risk assessment on certain pathogens in powdered infant formula following the global distribution of contaminated ByHeart products. At the Codex Committee on Food Hygiene meeting in December in Nashville, members asked the Joint
You don't have permission to access "http://www.medpagetoday.com/washington-watch/washington-watch/119153" on this server. Reference #18.af2d3e17.1766937708.c17ee1e4 https://errors.edgesuite.net/18.af2d3e17.1766937708.c17ee1e4
ByHeath Botulism Infant Formula – 51 Sick and Hospitalized As of December 17, 2025, this outbreak includes 51 infants with suspected or confirmed infant botulism from 19 states. Laboratory confirmation for some cases is ongoing. Illnesses started on dates ranging from December 24, 2023, through December 1, 2025. All 51 infants were hospitalized and treated with BabyBIG®. No